HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Kansas Medical Center
About this trial
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.
Eligibility criteria
Qualifiers
Patients must be 18 years of age or older
Patients must have bothersome lower urinary tract symptoms (LUTS), defined by American Urological Association Symptom Score (AUA SS) of greater than or equal to 15 and/or as defined by a post-void residual of greater than or equal to 350mL and/or as defined by catheter dependence
Patients must be diagnosed with prostate cancer by pathological tissue analysis
Patients must have elected for radiation with androgen deprivation therapy as the primary treatment modality for their prostate cancer
Disqualifiers
Patients who are under 18 years of age are not eligible
Patients who have a diagnosis of bladder cancer are not eligible.
Patients with prior treatment for prostate cancer are not eligible.
Patients with any type of prior prostate surgery (minimally invasive, endoscopic, or otherwise) including prior transurethral resection of the prostate (but excluding prior prostate biopsy) are ineligible.
Trial design
Treatments tested in this trial
- Holmium Laser Enucleation of Prostate (HoLEP)
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
1University of Kansas Health System66160, Kansas CityKansas, United States
Sponsors and collaborators
University of Kansas Medical Center
Lead sponsor
Source ClinicalTrials.gov